IP Library Granted Patent US 6,987,185
Granted Patent B2
US 6,987,185 · App. 10/478,602 · Granted Jan 17, 2006

Method for separating methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidine-carboxylate-recemate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,987,185
App. No.
10/478,602
Granted
Jan 17, 2006
Kind
B2
Abstract

The enantiomers of methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl)-1,4-dihydro-5-pyrimidinecarboxylate can be separated with the aid of (−)-camphanic acid.

Claims (5)

1. A method for resolving a mixture of the enantiomers of methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate comprising the steps of adding (−)-camphanic acid to form a mixture of diastereomeric (−)-camphanic salts, and separating said salts.

2. The method as claimed in claim 1 , wherein the (−)-camphanic acid salts of (D/L)-methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate are separated by crystallization, and each enantiomer is liberated with base, and isolated where appropriate, from the removed solid (−)-camphanic acid salt and/or from the removed solution.

3. The method as claimed in claim 1 , wherein the more soluble diastereomer is dissolved out of the mixture of the (−)-camphanic acid salts of(D/L)-methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate, the resulting solution is separated from the less soluble diastereomer, and each enantiomer is liberated with base, and isolated where appropriate, from the removed solid (−)-camphanic acid salt and/or from the removed solution.

4. D-Methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate (−)-camphanic acid salt.

5. L-Methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidinecarboxylate (−)-camphanic acid salt.

Assignments (4)
CHANGE OF NAME Recorded Apr 12, 2013
From: BAYER SCHERING PHARMA AG
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030202/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 029908/0217 →
MERGER Recorded Jan 12, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 023769/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2005
From: GOLDMANN, SIEGFRIED; FEY, PETER
To: BAYER HEALTHCARE AG
Reel/Frame 016187/0626 →